ABP 234

Phase 3Small molecule

Amgen

ABP 234 is one of 80 small molecule programs targeting Pembrolizumab. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PembrolizumabRecruiting

Non-Small Cell Lung CancerActive, not recruiting

PembrolizumabPhase 3

Recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Phase 3

11 2

Glumetinib

HHaihe Biopharma Co., Ltd.

Phase 3

5 3

ABP 234

Amgen

Phase 3

3 4

HD204

PPrestige Biopharma Limited

Phase 3

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 8

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Pembrolizumab

NCT06430866

Q4 2027

Phase 3Active, not recruiting

Relapsing Remitting Multiple Sclerosis (RRMS)

NCT06700343

Q1 2028

Phase 3Active, not recruiting

Metastatic Melanoma

NCT06054555

Q2 2028

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT06311721

Clinical

Trials by Indication[1]

Psoriasis4 trials

A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis

Completed· Amgen logo

Amgen·Phase 3·NCT05073315·425 enrolled

Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis

Completed· Amgen logo

Amgen·Phase 3·NCT01970488·350 enrolled

A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Completed· Amgen logo

Amgen·Phase 3·NCT04761627·494 enrolled

Show 1 more trial

A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Completed· Amgen logo

Amgen·Phase 3·NCT04607980·563 enrolled

Rheumatoid Arthritis4 trials

Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

Completed· Amgen logo

Amgen·Phase 3·NCT02792699·311 enrolled

Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab

Completed· Amgen logo

Amgen·Phase 3·NCT02937701·558 enrolled

Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Completed· Amgen logo

Amgen·Phase 3·NCT01970475·526 enrolled

Show 1 more trial

Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis

Completed· Amgen logo

Amgen·Phase 3·NCT02114931·467 enrolled

Non-Small Cell Lung Cancer3 trials

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT06311721·315 enrolled

A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

Withdrawn· Amgen logo

Amgen·Phase 3·NCT04466917

Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Completed· Amgen logo

Amgen·Phase 3·NCT01966003·642 enrolled

Adalimumab2 trials

Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants

Completed· Amgen logo

Amgen·Phase 1·NCT05995691·179 enrolled

A Randomized, Single-blind, Single-dose, 2-arm, Parallel-group Study to Determine the Pharmacokinetic Comparability of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 mL (ABP 501-LCF) in Healthy Adult Subjects

Completed· Amgen logo

Amgen·Phase 1·NCT05909852·372 enrolled

Pembrolizumab1 trial

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

Recruiting· Amgen logo

Amgen·Phase 3·NCT06430866·154 enrolled

8 more indications

Metastatic Melanoma1 trial

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT06054555·633 enrolled

Vascular Disease1 trial

A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

Completed· Amgen logo

Amgen·Phase 3·NCT05704725·49 enrolled

Efficacy and Safety1 trial

A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH

Completed· Amgen logo

Amgen·Phase 3·NCT03818607·42 enrolled

Lymphoma1 trial

Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab

Completed· Amgen logo

Amgen·Phase 3·NCT02747043·256 enrolled

Breast Cancer1 trial

Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer

Completed· Amgen logo

Amgen·Phase 3·NCT01901146·725 enrolled

Melanoma1 trial

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Completed· Amgen logo

Amgen·Phase 3·NCT05907122·256 enrolled

Age-Related Macular Degeneration1 trial

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Completed· Amgen logo

Amgen·Phase 3·NCT04270747·576 enrolled

Relapsing Remitting Multiple Sclerosis (RRMS)1 trial

A Randomized, Double-blind Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics, and Clinical Effects Between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT06700343·152 enrolled

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for ABP 234. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABP 234 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABP 234. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Amgen

ABP 234

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Psoriasis4 trials

Rheumatoid Arthritis4 trials

Non-Small Cell Lung Cancer3 trials

Adalimumab2 trials

Pembrolizumab1 trial

Metastatic Melanoma1 trial

Vascular Disease1 trial

Efficacy and Safety1 trial

Lymphoma1 trial

Breast Cancer1 trial

Melanoma1 trial

Age-Related Macular Degeneration1 trial

Relapsing Remitting Multiple Sclerosis (RRMS)1 trial

References

Drug Info

Quick Facts

Related News